STOCK TITAN

Cardio Diagnostics Holdings Inc - CDIO STOCK NEWS

Welcome to our dedicated page for Cardio Diagnostics Holdings news (Ticker: CDIO), a resource for investors and traders seeking the latest updates and insights on Cardio Diagnostics Holdings stock.

Cardio Diagnostics Holdings Inc (NASDAQ: CDIO) is a biotechnology company at the forefront of advancing cardiovascular disease prevention, early detection, and management. Leveraging its proprietary Genetic-Epigenetic Engine™, the company integrates artificial intelligence with genetic and epigenetic data to deliver personalized and precise diagnostic solutions. This innovative approach addresses a critical medical need, as cardiovascular disease remains one of the leading causes of death globally.

Core Business and Technology

Cardio Diagnostics specializes in developing and commercializing advanced diagnostic tools that empower healthcare providers to improve patient outcomes. By combining genetic predisposition data with epigenetic markers, the company's technology provides a more comprehensive understanding of an individual's cardiovascular health. This integrated approach enables earlier detection of risk factors, more effective prevention strategies, and tailored treatment plans, aligning with the growing trend toward personalized medicine.

Market Position and Industry Context

Operating within the rapidly evolving biotechnology and medical technology sectors, Cardio Diagnostics is well-positioned to capitalize on the increasing demand for AI-driven healthcare solutions. The global push for precision medicine and the integration of big data analytics in healthcare provide a favorable backdrop for the company's growth. Its focus on cardiovascular health—a field with significant unmet needs—further strengthens its market relevance.

Value Proposition

The company's unique value lies in its ability to bridge the gap between genetic predisposition and real-time health insights. Traditional diagnostic tools often rely solely on genetic information, which can only indicate potential risks. Cardio Diagnostics' incorporation of epigenetic data provides a dynamic view of how lifestyle and environmental factors influence gene expression, offering actionable insights for both patients and clinicians. This capability not only enhances diagnostic accuracy but also supports preventive healthcare measures, reducing long-term healthcare costs.

Business Model and Revenue Streams

Cardio Diagnostics generates revenue through the sale of its diagnostic tests, licensing agreements for its proprietary technology, and partnerships with healthcare providers and institutions. By integrating its solutions into clinical workflows, the company aims to establish itself as an essential partner in cardiovascular care. Additionally, its AI-driven platform offers scalability, enabling the potential expansion into other areas of chronic disease management.

Challenges and Differentiation

While the company operates in a competitive landscape alongside other medical technology firms, its focus on the intersection of genetics, epigenetics, and artificial intelligence sets it apart. Regulatory compliance and the need for robust clinical validation are ongoing challenges, but these are common across the industry and are mitigated by the company's commitment to scientific rigor. Its proprietary technology and emphasis on personalized care provide a strong competitive edge.

Impact and Future Potential

Cardio Diagnostics is not just addressing a medical need but is also contributing to a broader shift in healthcare toward prevention and personalization. By making cardiovascular diagnostics more accessible and precise, the company is poised to play a transformative role in reducing the global burden of heart disease. Its innovative use of AI and epigenetics represents a significant step forward in the integration of technology and medicine, offering hope for improved patient outcomes and more efficient healthcare systems.

Rhea-AI Summary
Cardio Diagnostics Holdings, an AI-driven precision cardiovascular medicine company (Nasdaq: CDIO), introduces HeartRisk to help employers understand and mitigate cardiovascular risks in their workforce. HeartRisk provides actionable insights related to cardiovascular disease, such as the amount of stop-loss insurance to carry based on the degree of CVD risk in the relevant population or selections of appropriate chronic care management partners.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
none
-
Rhea-AI Summary
CARDIO DIAGNOSTICS HOLDINGS, INC. (Nasdaq: CDIO) introduces HeartRisk™, an employer cardiovascular disease risk intelligence platform to combat cardiovascular disease in the workforce and mitigate business risks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
none
-
Rhea-AI Summary
Cardio Diagnostics Holdings, an AI-driven precision cardiovascular medicine company (Nasdaq: CDIO), has received a dedicated CPT PLA code, 0439U, from the American Medical Association for its AI-powered coronary heart disease event risk assessment test, Epi+Gen CHD. This milestone will accelerate reimbursement from federal and private payers, increasing access to precision cardiovascular medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
AI
Rhea-AI Summary
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) has achieved a milestone by obtaining a dedicated Current Procedural Terminology (CPT) Proprietary Laboratory Analysis (PLA) code, 0440U, from the American Medical Association (AMA) for its AI-driven coronary heart disease (CHD) detection test, PrecisionCHD. This will facilitate reimbursement from federal and private payers and expand access to the innovative test. The CPT PLA code will be effective on April 1, 2024, and is a significant step toward broader adoption of the first and only integrated genetic-epigenetic diagnostic blood test for CHD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.89%
Tags
AI
-
Rhea-AI Summary
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) appoints Paul Burton, J.D., MBA as Independent Director, bringing over 20 years of experience in medical technology innovation, corporate finance, and shaping the strategy and operations of growth-stage companies. Mr. Burton will Chair the Nominating and Corporate Governance Committee and serve as a member of the Audit Committee. His expertise in healthcare investing, growth strategy, and FDA navigation will be invaluable in advancing Cardio Diagnostics' vision of using advanced diagnostics for more personalized cardiovascular care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.48%
Tags
management
-
Rhea-AI Summary
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) has regained compliance with the minimum bid price requirement set forth by Nasdaq, ensuring continued listing on The Nasdaq Capital Market. The company's common stock maintained a minimum closing bid price of $1.00 or more for 10 consecutive business days, from November 20, 2023, to December 4, 2023, leading to Nasdaq closing the matter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
none
Rhea-AI Summary
Cardio Diagnostics Holdings, a leader in artificial intelligence-driven precision cardiovascular medicine tests, will be attending the 42nd Annual J.P. Morgan Healthcare Conference from January 8 to 11, 2024, in San Francisco, CA. The company's management will be presenting a roundtable session titled 'Operationalizing Value-Based Care in Shared Risk Contracts: A Novel Model for Heart Disease Risk Management' to discuss risk mitigation strategies across the cardiovascular medicine continuum. The roundtable will bring together healthcare stakeholders to discuss operationalizing value-based care with novel risk-stratification strategies in the cardiovascular disease space.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.74%
Tags
none
-
Rhea-AI Summary
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) is convening a roundtable at the 42nd Annual J.P. Morgan Healthcare Conference to discuss operationalizing value-based care with novel risk-stratification strategies in the cardiovascular disease space. The company's management will be attending the conference from January 8 to 11, 2024, in San Francisco, CA. The roundtable will bring together healthcare stakeholders to facilitate the development of more robust value-based care models for tackling heart disease risks to support better patient outcomes and innovative payer models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.74%
Tags
none
-
Rhea-AI Summary
Cardio Diagnostics Holdings, a leader in AI-driven precision cardiovascular medicine tests, announced that the AMA is reviewing its Epi+Gen CHD and PrecisionCHD tests for CPT PLA codes. If approved, the codes are expected to be published by January 1, 2024, and will be effective on April 1, 2024. This move would be a significant step towards securing federal and private payer reimbursement for the tests, streamlining the reimbursement process and facilitating broader adoption of Cardio's next-generation cardiovascular tests.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.75%
Tags
none
Rhea-AI Summary
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) announced the publication of a groundbreaking study in the Journal of the American Heart Association (JAHA) detailing the development and validation of PrecisionCHD, an artificial intelligence-guided integrated genetic-epigenetic test for detecting coronary heart disease (CHD). The test, a blood-based alternative to invasive and costly traditional methods, uses AI and personalized genetic and epigenetic information to sensitively detect CHD. The study, conducted in collaboration with Intermountain Healthcare and University of Iowa Hospitals and Clinics, involved 2,516 individuals and marks a significant leap in CHD diagnosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
123.23%
Tags
none

FAQ

What is the current stock price of Cardio Diagnostics Holdings (CDIO)?

The current stock price of Cardio Diagnostics Holdings (CDIO) is $0.4212 as of March 3, 2025.

What is the market cap of Cardio Diagnostics Holdings (CDIO)?

The market cap of Cardio Diagnostics Holdings (CDIO) is approximately 22.2M.

What does Cardio Diagnostics Holdings Inc do?

Cardio Diagnostics develops AI-driven diagnostic tools that integrate genetic and epigenetic data for the prevention and early detection of cardiovascular disease.

How does Cardio Diagnostics' technology work?

The company uses its proprietary Genetic-Epigenetic Engine™ to analyze genetic predisposition and epigenetic markers, providing personalized insights into cardiovascular health.

What makes Cardio Diagnostics different from other diagnostic companies?

Cardio Diagnostics combines genetic and epigenetic data with artificial intelligence, offering a more dynamic and comprehensive approach to cardiovascular diagnostics.

What industry does Cardio Diagnostics operate in?

The company operates in the biotechnology and medical technology sectors, focusing on precision medicine and AI-driven healthcare solutions.

How does Cardio Diagnostics generate revenue?

Revenue is generated through the sale of diagnostic tests, licensing of its proprietary technology, and partnerships with healthcare providers.

What challenges does Cardio Diagnostics face?

The company faces challenges such as regulatory compliance, clinical validation, and competition from other medical technology firms.

What is the Genetic-Epigenetic Engine™?

It is Cardio Diagnostics' proprietary platform that integrates genetic and epigenetic data to provide actionable insights for cardiovascular disease prevention and management.

What is the significance of epigenetics in diagnostics?

Epigenetics provides insights into how lifestyle and environmental factors influence gene expression, enabling a more dynamic understanding of health risks.

Who are the target customers for Cardio Diagnostics?

The company's solutions are designed for healthcare providers, institutions, and patients seeking personalized and precise cardiovascular care.

What is the broader impact of Cardio Diagnostics' work?

By improving the accessibility and precision of cardiovascular diagnostics, the company is helping to reduce the global burden of heart disease and advance personalized medicine.
Cardio Diagnostics Holdings Inc

Nasdaq:CDIO

CDIO Rankings

CDIO Stock Data

22.17M
36.43M
9.86%
4.15%
5.49%
Biotechnology
In Vitro & in Vivo Diagnostic Substances
Link
United States
CHICAGO